Beyond the putative role of hypertension-linked AF, the inhibition of the PI3K-Akt pathway by ibrutinib may also play a pathogenic role in the development of AF, but it is still controversial [35–37]. The gene discussed is AKT1; the disease is atrial fibrillation.